May 04, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
CHICAGO — Even with biologics changing the treatment paradigm for ulcerative colitis more than 2 decades ago, patients have a similar risk for undergoing colectomy a decade after diagnosis as they have had for the last 5 decades.The findings were presented at Digestive Disease Week.
May 04, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

The risk for major adverse cardiovascular events appeared similar between older patients treated with 5-aminosalicylic acid and…

The HLA-DRB1*01:03 allele was associated with severe outcomes across inflammatory bowel disease subtypes, including perianal…

Among biologic-naive patients with moderate to severe ulcerative colitis, upadacitinib and infliximab had the quickest onset and…

CHICAGO — Combining golimumab and guselkumab into JNJ-78934804, a fixed-dose co-antibody therapy, helped overcome treatment…

Clinicians should carefully monitor patients with inflammatory bowel disease and comorbid Clostridioides difficile infection,…

In over 90% of cases, an AI-based clinical decision support system delivered colonoscopy surveillance intervals aligned with…